Not Yet RecruitingNot Applicable

Ravulizumab Outcomes in Polish Patients With aHUS

80 participantsStarted 2026-04-01

Plain-language summary

This multicenter, observational cohort study uses retrospective collection of past medical history and prospective follow-up to capture longitudinal data on the management and clinical outcomes of patients with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab as part of routine clinical practice under Poland's National Drug Program (NDP).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients of all ages diagnosed with atypical hemolytic uremic syndrome (aHUS) who received treatment with ravulizumab under the National Drug Program (NDP) in Poland. * Patients who are willing to participate in the study and have provided informed consent by signing the informed consent form (ICF). Exclusion Criteria: * Individuals who intend to participate in a clinical trial for atypical hemolytic uremic syndrome (aHUS) on or after the date of their first ravulizumab infusion through the National Drug Program. * Patients with cognitive impairments, those who are unwilling to participate, or those facing language barriers that hinder adequate comprehension or cooperation.

What they're measuring

Proportion of patient attaining Complete Thrombotic Microangiopathy (TMA) Response during observation (naïve)

Timeframe: Up to 24 months

Proportion of patients attaining/maintaining. Complete TMA Response during observation (switched)

Timeframe: Up to 24 months

Trial details

NCT IDNCT07399730

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2030-12-31

Contact for this trial

AstraZeneca Clinical Study Information Center Study Information Center

+118772409479 information.center@astrazeneca.com